Loading stock data…
Neuphoria Therapeutics Inc. (NEUP)
$3.75-0.02 (-0.53%)
Market ClosedLast close Sep 8
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neuphoria Therapeutics Inc. in the Healthcare sector is trading at $3.75 with a market capitalization of $25M. The stock is currently near its 52-week low of $3.19, remaining 12.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $15.00M↑ | $662,715 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$827,284↑ | -$2.35M↑ | -$5.65M↓ | $11.97M↑ | -$3.40M |
| Net Income | -$505,063↓ | $1.86M↑ | -$9.91M↓ | $11.26M↑ | -$1.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$25.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.23%
Volume
Today's trading volume
22,596
Recent News
Scancell sees high demand in retail share offer, seals £15.7m from UK investors
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) confirmed the UK leg of its equity funding has raised gross proceeds of £15.7 million after strong retail demand prompted the cancer immunotherapy developer to increase the size of its retail offer. The retail offer raised £2.7...
SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) saw its shares drop 27% this week, but the movement obscures the real story, which is a largely positive one for investors. It may take the market a while to process some transformational changes that will see the oncology research...
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell
Neuphoria Therapeutics (NEUP) and Scancell Holdings said Thursday they have agreed to an all-stock m
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the Oxford-based cancer immunotherapy developer listed on London's junior AIM market, has agreed an all-share merger with US biotech Neuphoria Therapeutics that will give it a Nasdaq listing and access to American investors. The combined...
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership
Merck cited business reasons for the discontinuation of the investigational drug.